Plasma levels of tissue plasminogen activator-inhibitor complex (t-PAIC) in patients with acute myocardial Infarction: An observational study

Abstract Introduction: The activation of the plasmatic coagulation system significantly contributes to acute myocardial infarction (AMI). This study aimed to assess the association between tissue plasminogen activator-inhibitor complex (t-PAIC), thrombin-antithrombin complex (TAT), plasmin-α2 plasmin-inhibitor complex (PIC), and thrombomodulin (TM) with clinical outcomes in patients with AMI. Methods: Blood samples were taken from 368 patients with acute myocardial infarction in the emergency room to measure t-PAIC, TAT, PIC, and TM levels. The patients were followed up for 6 months. Results: t-PAIC levels were considerably elevated in AMI patients who died compared to those who survived. Additionally, t-PAIC levels were greater in the major adverse cardiovascular events (MACE) group than in the non-MACE group among surviving patients throughout follow-up. Linear regression analysis indicated that high levels of t-PAIC were linked to mortality following acute myocardial infarction and raised the likelihood of MACE in survivors. ROC curve study revealed that t-PAIC has predictive value for mortality following AMI. Analysis of the ROC curve and Kaplan-Meier survival curve demonstrated that t-PAIC was able to forecast MACE in individuals who had experienced an AMI. Conclusion: Our data suggest that elevated t-PAIC levels increase the mortality rate of AMI patients and increase the 6-month incidence of MACE in AMI survivors.